SCHEMBL7969774

SCHEMBL7969774

COc1cc(C(=O)N(C)c2ccc(C)cc2OCc2ccc(C(=O)N3CCN(C)CC3)cc2)ccc1NC(=O)c1cccc2c1nc(C(=O)OC(C)(C)C)n2CN

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 2/20 0.38
JAK2 O60674 1/20 0.35
USP2 O75604 1/20 0.34
HPGD P15428 1/20 0.34
TTK P33981 2/20 0.33
LCK P06239 1/20 0.33
MERTK Q12866 1/20 0.33
AVPR2 P30518 2/20 0.33
AVPR1A P37288 2/20 0.33
TLR9 Q9NR96 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
ADORA1 P30542 1/20 0.33
ALK Q9UM73 1/20 0.33
CCNT1 O60563 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CDK9 P50750 1/20 0.33
CCNA1 P78396 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7967095 0.91 BRD4 (0.37) TLR9TLR7
SCHEMBL7967359 0.89 AVPR2 (0.35) MAP3K7JAK2LCKAVPR2AVPR1A
SCHEMBL7966770 0.84 IRAK4 (0.34)
SCHEMBL7969777 0.83 JAK2 (0.39) MAP3K7JAK2USP2HPGDTTK
SCHEMBL7477796 0.82 MAP3K7 (0.41) MAP3K7JAK2USP2HPGDMERTK
Hydrochloric Acid SCHEMBL7973786 0.82 MAP3K7 (0.41) MAP3K7JAK2USP2HPGDMERTK
SCHEMBL7954760 0.76 AVPR2 (0.36) MAP3K7HPGDAVPR2AVPR1A
SCHEMBL7966222 0.76 AVPR2 (0.36) MAP3K7HPGDAVPR2AVPR1A
SCHEMBL7964596 0.75 AVPR2 (0.36) MAP3K7AVPR2AVPR1A
SCHEMBL7970647 0.75 MAP3K7 (0.38) MAP3K7LCKAVPR2AVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6316482-B1 FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-13 US disclosed